Dublin – October 12, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.
Ten-author analysis targets liver transplant-ineligible patients
The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.
Reau said the analysis expands the clinical evidence on terlipressin in transplant-ineligible patients and can help providers support those with HRS-AKI.
U.S. HRS inpatient volumes rose from 42,930 to 63,381 between 2018 and 2023
A U.S. study based on national data estimated the annual number of inpatients diagnosed with hepatorenal syndrome at 63,381 in 2023, up from 42,930 in 2018. HRS-AKI is a life-threatening condition in adults with advanced liver disease, marked by a rapid decline in kidney function. It is an acute medical emergency that requires hospitalization.
TERLIVAZ is the first and only FDA-approved therapy indicated to improve kidney function in adults with HRS-AKI.
Boxed warning flags fatal respiratory failure risk
TERLIVAZ carries a boxed warning for serious or fatal respiratory failure. Patients with volume overload or acute-on-chronic liver failure (ACLF) Grade 3 face higher risk. Treatment should not begin in hypoxic patients (SpO2 below 90%), and clinicians must monitor with continuous pulse oximetry.
The label notes that patients with serum creatinine above 5 mg/dL are unlikely to benefit. For patients with high liver transplant prioritization (MELD of 35 or higher), the benefits may not outweigh the risks. Adverse reactions may make a listed patient ineligible for transplant. The most common adverse reactions (10% or more) are abdominal pain, nausea, respiratory failure, diarrhea and dyspnea.